Initial results from BEACON, a phase 1b/2a dose escalation study of the anti-c-Kit briquilimab antibody in adults with chronic spontaneous urticaria (CSU)
2025 · Journal of Allergy and Clinical Immunology · 3 citations
https://doi.org/10.1016/j.jaci.2024.12.998